{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events.","groupId":"OG000","lowerLimit":"21.65","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"DOR for participants with a best overall response of CR was defined as the time from documentation of first response (or CR) to progressive disease (PD) or death, whichever occurred first. The first documentation of CR/PR is the latest of all dates of required measurements to establish the response. The progression date is the earliest date of all assessments that led to a response assessment of PD.\n\nCR = Score 1, 2, or 3 on the positron emission tomography 5-point scale (PET 5PS). A score of 3 indicates a good prognosis with standard treatment.\n\nPD = Score 4 or 5b on PET 5PS with an increase in intensity of uptake from baseline and/or new fluorodeoxyglucose-avid foci consistent with lymphoma at interim or end-of-treatment assessment.\n\nPET 5PS = 1-no uptake above background; 2-uptake ≤ mediastinum; 3-uptake \\> mediastinum but ≤ liver; 4-uptake moderately \\> liver; 5-uptake markedly higher than liver and/or new lesions; X- new areas of uptake unlikely to be related to lymphoma.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEDIAN","populationDescription":"All participants with PET positive disease who received at least one infusion of JCAR017 and achieved complete response (CR)","reportingStatus":"POSTED","timeFrame":"From first dose to up to approximately 24 months","title":"Duration of Response (DOR) in Participants With Complete Response (CR)","type":"SECONDARY","unitOfMeasure":"Months"}